{"abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Evotec International GmbH (Evotec), located in Hamburg, Germany.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2022/06/01/2022-11666.html","cfr_references":[],"citation":"87 FR 33176","comment_url":null,"comments_close_on":"2022-06-16","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before June 16, 2022 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2022-11666","effective_on":null,"end_page":33176,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2022/06/01/2022-11666.xml","html_url":"https://www.federalregister.gov/documents/2022/06/01/2022-11666/prospective-grant-of-an-exclusive-patent-license-the-development-of-an-anti-mesothelin-chimeric","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2022-11666?publication_date=2022-06-01","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2022-06-01/2022-11666/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":231,"last_updated":"2026-06-24 00:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2022-06-01/pdf/2022-11666.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2022-11666.pdf?1654001124","publication_date":"2022-06-01","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2022/06/01/2022-11666.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T22:12:14Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":33176,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: The Development of an Anti-Mesothelin Chimeric Antigen Receptor (CAR) for the Treatment of Mesothelin-Expressing Human Cancers","toc_doc":"The Development of an Anti-Mesothelin Chimeric Antigen Receptor for the Treatment of Mesothelin-Expressing Human Cancers","toc_subject":"Prospective Grant of an Exclusive Patent License:\n","topics":[],"type":"Notice","volume":87}